Univariate analysis for LFS, OS, relapse, and GVHD
| . | Relative risk (95% CI) . | P . |
|---|---|---|
| Treatment failure (inverse of LFS) | ||
| Disease status (within 1 mo of HCT) | ||
| CR1 | 1.00 | |
| CR2/CR3 | 0.54 (0.22-1.33) | .18 |
| Relapse/PIF | 2.46 (1.33-4.52) | .004 |
| Disease status (> 1 mo after HCT) | ||
| CR1 | 1.00 | |
| CR2/CR3 | 1.29 (1.02-1.65) | .03 |
| Relapse/PIF | 1.32 (1.01-1.74) | .04 |
| Performance score (within 4 mo of HCT) | ||
| < 90 | 1.00 | |
| 90-100 | 0.68 (0.50-0.90) | .007 |
| Performance score (> 4 mo of HCT) | ||
| < 90 | 1.00 | |
| 90-100 | 1.13 (0.84-1.52) | .42 |
| Overall mortaiity | ||
| Disease status | ||
| CR1 | 1.00 | |
| CR2/CR3 | 1.23 (0.96-1.57) | .10 |
| Relapse/PIF | 1.50 (1.16-1.94) | .002 |
| Performance score (within 4 mo of HCT) | ||
| < 90 | 1.00 | |
| 90-100 | 0.75 (0.59-0.96) | .02 |
| Performance score (> 4 mo of HCT) | ||
| < 90 | 1.00 | |
| 90-100 | 1.26 (0.78-2.03) | .35 |
| Relapse | ||
| Disease status (within 1 mo of HCT) | ||
| CR1 | 1.00 | |
| CR2/CR3 | 0.44 (0.15-1.31) | .14 |
| Relapse/PIF | 2.43 (1.23-4.80) | .01 |
| Disease status (> 1 mo after HCT) | ||
| CR1 | 1.00 | |
| CR2/CR3 | 1.49 (1.09-2.02) | .01 |
| Relapse/PIF | 1.65 (1.18-2.31) | .004 |
| Grade II-IV acute GVHD | ||
| Year of transplantation | ||
| 2001-2004 | 1.00 | |
| 2005-2009 | 0.73 (0.55-0.97) | .03 |
| Grade III-IV acute GVHD | ||
| Year of transplantation | ||
| 2001-2004 | 1.00 | |
| 2005-2009 | 0.63 (0.42-0.95) | .03 |
| Chronic GVHD | ||
| CMV serostatus | ||
| Sero-positive | 1.00 | |
| Sero-negative | 1.30 (1.02-1.65) | .03 |
| Performance score | ||
| < 90 | 1.00 | |
| 90-100 | 0.78 (0.61-1.01) | .06 |
| Year of transplantation | ||
| 2001-2004 | 1.00 | |
| 2005-2009 | 0.56 (0.43-0.73) | < .001 |
| . | Relative risk (95% CI) . | P . |
|---|---|---|
| Treatment failure (inverse of LFS) | ||
| Disease status (within 1 mo of HCT) | ||
| CR1 | 1.00 | |
| CR2/CR3 | 0.54 (0.22-1.33) | .18 |
| Relapse/PIF | 2.46 (1.33-4.52) | .004 |
| Disease status (> 1 mo after HCT) | ||
| CR1 | 1.00 | |
| CR2/CR3 | 1.29 (1.02-1.65) | .03 |
| Relapse/PIF | 1.32 (1.01-1.74) | .04 |
| Performance score (within 4 mo of HCT) | ||
| < 90 | 1.00 | |
| 90-100 | 0.68 (0.50-0.90) | .007 |
| Performance score (> 4 mo of HCT) | ||
| < 90 | 1.00 | |
| 90-100 | 1.13 (0.84-1.52) | .42 |
| Overall mortaiity | ||
| Disease status | ||
| CR1 | 1.00 | |
| CR2/CR3 | 1.23 (0.96-1.57) | .10 |
| Relapse/PIF | 1.50 (1.16-1.94) | .002 |
| Performance score (within 4 mo of HCT) | ||
| < 90 | 1.00 | |
| 90-100 | 0.75 (0.59-0.96) | .02 |
| Performance score (> 4 mo of HCT) | ||
| < 90 | 1.00 | |
| 90-100 | 1.26 (0.78-2.03) | .35 |
| Relapse | ||
| Disease status (within 1 mo of HCT) | ||
| CR1 | 1.00 | |
| CR2/CR3 | 0.44 (0.15-1.31) | .14 |
| Relapse/PIF | 2.43 (1.23-4.80) | .01 |
| Disease status (> 1 mo after HCT) | ||
| CR1 | 1.00 | |
| CR2/CR3 | 1.49 (1.09-2.02) | .01 |
| Relapse/PIF | 1.65 (1.18-2.31) | .004 |
| Grade II-IV acute GVHD | ||
| Year of transplantation | ||
| 2001-2004 | 1.00 | |
| 2005-2009 | 0.73 (0.55-0.97) | .03 |
| Grade III-IV acute GVHD | ||
| Year of transplantation | ||
| 2001-2004 | 1.00 | |
| 2005-2009 | 0.63 (0.42-0.95) | .03 |
| Chronic GVHD | ||
| CMV serostatus | ||
| Sero-positive | 1.00 | |
| Sero-negative | 1.30 (1.02-1.65) | .03 |
| Performance score | ||
| < 90 | 1.00 | |
| 90-100 | 0.78 (0.61-1.01) | .06 |
| Year of transplantation | ||
| 2001-2004 | 1.00 | |
| 2005-2009 | 0.56 (0.43-0.73) | < .001 |
LFS indicates leukemia-free survival; OS, overall survival; CI, confidence interval; PIF, primary induction failure; and HCT, hematopoietic cell transplant.